Form 4: Revolution Medicines COO Margaret Horn Sells Shares to Cover Tax Obligations

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 3,058 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On March 17, 2025, Margaret Horn, the Chief Operating Officer of Revolution Medicines, sold 3,058 shares of the company's common stock.
• The sale was executed at a price of $39.0403 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
• Following the transaction, Horn still beneficially owns 153,533 shares of Revolution Medicines, including 89,050 RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale of shares under a pre-arranged trading plan for tax purposes.

Industry Context

Sales by company insiders are a normal part of corporate governance, especially when related to covering tax obligations on vested equity. The use of a pre-arranged 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The sale of shares to cover tax obligations is a common practice among executives in publicly traded companies.
• Using a 10b5-1 trading plan is a standard method to ensure compliance with insider trading regulations, similar to practices at companies like Amgen, Gilead, and Vertex.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Revolution Medicines, RVMD, Margaret Horn, Chief Operating Officer, Form 4, Stock Sale, Rule 10b5-1, Restricted Stock Units, RSUs, Beneficial Ownership, Insider Trading